Literature DB >> 32007241

Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist.

Alexandra L Lewis1, Jamie Chaft2, Monica Girotra3, Gregory W Fischer2.   

Abstract

Immunotherapy has revolutionised the treatment of oncologic malignancies. Immune checkpoint inhibitors represent a new class of immunotherapy drugs. Although these drugs show promise, they are associated with immune-related adverse reactions. An increasing number of patients who undergo surgery will have had treatment with immune checkpoint inhibitors. In this narrative review article, we discuss their mechanism of action, therapeutic effects, pertinent toxicities, and address specific perioperative considerations for patients treated with immune checkpoint inhibitors.
Copyright © 2019 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  adverse events; anaesthesia; cancer; complications; immune checkpoint inhibitors; immunotherapy; perioperative management; side effects

Mesh:

Substances:

Year:  2020        PMID: 32007241     DOI: 10.1016/j.bja.2019.11.034

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  9 in total

Review 1.  Anaesthesia after neoadjuvant chemotherapy, immunotherapy or radiotherapy.

Authors:  M D Groenewold; C G Olthof; D J Bosch
Journal:  BJA Educ       Date:  2021-10-16

2.  PYCR1 regulates glutamine metabolism to construct an immunosuppressive microenvironment for the progression of clear cell renal cell carcinoma.

Authors:  Xiyi Wei; Xi Zhang; Shuai Wang; Yichun Wang; Chengjian Ji; Liangyu Yao; Ninghong Song
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

Review 3.  Cancer Immunotherapies: What the Perioperative Physician Needs to Know.

Authors:  Robert S Ackerman; Aaron R Muncey; Nasrin N Aldawoodi; Rohini Kotha; Rosemarie E Garcia Getting
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.945

Review 4.  Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer.

Authors:  Ke-Tao Jin; Bo Chen; Yu-Yao Liu; H Uan-Rong Lan; Jie-Ping Yan
Journal:  Cancer Cell Int       Date:  2021-02-01       Impact factor: 5.722

Review 5.  Polymeric Micelles in Cancer Immunotherapy.

Authors:  Zhuoya Wan; Ruohui Zheng; Pearl Moharil; Yuzhe Liu; Jing Chen; Runzi Sun; Xu Song; Qiang Ao
Journal:  Molecules       Date:  2021-02-25       Impact factor: 4.411

Review 6.  Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy.

Authors:  Elizabeth R Hawkins; Reena R D'Souza; Astero Klampatsa
Journal:  Biologics       Date:  2021-04-14

7.  IGF1R signalling is a guardian of self-tolerance restricting autoantibody production.

Authors:  Malin C Erlandsson; Seval Erdogan; Caroline Wasén; Karin M E Andersson; Sofia T Silfverswärd; Rille Pullerits; Mats Bemark; Maria I Bokarewa
Journal:  Front Immunol       Date:  2022-08-29       Impact factor: 8.786

Review 8.  COVID-19 in the Cancer Patient.

Authors:  Cindy B Yeoh; Kathleen J Lee; Elizabeth F Rieth; Renee Mapes; Anna V Tchoudovskaia; Gregory W Fischer; Luis E Tollinche
Journal:  Anesth Analg       Date:  2020-07       Impact factor: 5.108

Review 9.  A review on the advances and challenges of immunotherapy for head and neck cancer.

Authors:  Gang Cheng; Hui Dong; Chen Yang; Yang Liu; Yi Wu; Lifen Zhu; Xiangmin Tong; Shibing Wang
Journal:  Cancer Cell Int       Date:  2021-07-31       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.